Slide 1: Presentation context at ECCMID 2023 Pipeline Corners Session
The following slides were presented by Robert J. DeLuccia, Executive Chairman of Acurx, who was an invited speaker at the Pipeline Corners Session at ECCMID 2023 Chaired by Dr. Ursula Theuresbacher. He was asked to gear his talk to address the following: An introduction to the Company, the concept o
Slide 2: First of a New Class of Antibiotics Targeting Priority Pathogens
First of a New Class of Antibiotics Targeting “Priority Pathogens” Preparing for the Next Pandemic: Antimicrobial Resistance Robert J. DeLuccia Executive Chairman ECCMID 2023: Pipeline Corner April 15,2023 2
Slide 3: Disclosure: Forward-Looking Statements
Disclosure Acurx Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, development plans, regulatory activities, anticipated milestones, product candidate benefits, competitiv
Slide 4: AMR: Global Challenge
AMR: GLOBAL CHALLENGE Acurx Valeria Gigante, Ph.D. (Geneva Switzerland) Not enough new antibiotics in the pipeline; Most are not Team Lead, AMR Division, WHO new drug classes but evolution of existing classes; R&D Co-Chair: WHO AMR Impact Initiatives and process challenging and poorly funded; last n
Slide 5: Acurx Snapshot
Acurx Snapshot Acurx Novel Mechanism of Action: §Previously unexploited scientific target §Lead pol IIIC Inhibitor discovered by Wright/Brown Professors Emeriti, UMass; Acurx acquired in 20181 §Innovation criteria2: ü New chemical class ü New target (Gram+; now clinically validated) ü New MOA (Uniqu
Slide 6: Systemic GPSS Antibiotic: Program Highlights
Systemic GPSS™ Antibiotic: Program Highlights Acurx Systemic Pol IIIC Inhibitor Program: Oral and IV formulations to target systemic treatment of Staphylococcus, Streptococcus and Enterococcal infections, including MRSA, VRE, and other resistant G+ bacterial infections; WHO/CDC Priority Pathogen Lis
Slide 7: Systemic GPSS Antibiotic: Program Goal / Progress
Systemic GPSS Antibiotic: Program Goal / Progress Acurx ™ § Hit-to-Lead testing of >500 novel compounds resulted in significant improvements in: § Cytotoxicity, solubility, plasma protein binding § In vitro & in vivo safety § Oral and IV efficacy in mouse infection models including in neutropenic mi
Slide 8: Benefits and Challenges of Developing a New Class of Antibiotics
Benefits and Challenges of Developing a New Acurx Class of Antibiotics For Society and Patients § Match up the societal challenge of AMR evolution to the opportunity and probability of success to commercialize a new therapeutic for serious and life-threatening infections § Novel treatments for multi
Slide 9: Benefits and Challenges of Developing a New Class of Antibiotics
Benefits and Challenges of Developing a New Acurx Class of Antibiotics Scientific Challenges and Pursuit of Commercialization of a new antibiotic § Need sophisticated scientific tools, talent and collaborations to enhance medicinal chemistry efforts § Novel analogs of pol IIIC inhibitors with improv
Slide 10: Outlook / Vision: Next 5 years
Outlook / Vision: Next 5 years Acurx § AMR treatable with new classes of antibiotics with appropriate antibiotic stewardship § Acurx market introduction of ibezapolstat for first-line treatment of CDI § Acurx advances lead Oral and IV antibiotic candidate for pan-active Gram+ infections into Ph2 cli
Slide 11: No new class of antibiotics discovered and approved in decades
No new class of antibiotics discovered and approved in decades …Acting NOW to replenish the pipeline with novel antibiotics to treat infections caused by Gram+ organisms Please visit our website: www.acurxpharma.com ACXP: Nasdaq Contact: Bob DeLuccia 914-949-3898 rjdeluccia@acurxpharma.com 11